The journey of canakinumab; on- and off-label indications

Abstract

The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarize the on- and off-label use of canakinumab (ILARIS).

Keywords

• il-1β
• inflammation
• interleukin 1
• rheumatic disease
• il-1 inhibitors
• auto-inflammatory disease
• caps
• traps
• biological therapies
• familial mediterranean fever
• adult-onset still disease
• sjia
• hids
• pregnancy